Pipeline
Two programs in skin health, and a pipeline behind them.
Two leads, a bench of follow-on compounds, and two library screens.
| Program | C. elegans screen | Human cells | Mammalian model | Human |
|---|---|---|---|---|
| Clinical-track leadTopical · radiation dermatitis | ||||
| Consumer-track leadBotanical-derived active · cosmetic photoaging | ||||
| Resilience benchFollow-on compounds with human-cell data | ||||
| Peptide initiativeClinical and OTC peptide library | ||||
| UV-resilience screen (RadBot)500-compound natural-product library |
The resilience bench
Compounds behind the two leads, each with human-cell data, across DNA-damage response, wound repair, inflammation, vascular integrity and cellular longevity.
The peptide initiative
A clinical- and OTC-peptide library through the same lifespan screen. The first 468 have returned, and the full dataset is planned for public release on completion.
What comes next
Two additions: gene-expression readouts on the robot, so each screen reports mechanism as well as outcome, and a screen of natural-product combinations.
Federal programs
Two federal awards and a third selected for funding, each peer reviewed.
Radiation Resilience
Phase I awardedCompounds that protect healthy tissue against radiation injury. Our clinical-track lead came out of this program.
EleGantry
Phase I awardedThe screening infrastructure itself: the hardware and software that make screening at this scale possible.
RadBot
Selected · award pendingAutomated UV-resilience screening of a 500-compound natural-product library, with human-cell validation downstream.